Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.

Jurcic, J G

Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. [electronic resource] - Leukemia Feb 1995 - 244-8 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

0887-6924


Adult
Aged
Antibodies, Monoclonal--adverse effects
Antigens, CD--immunology
Antigens, Differentiation, Myelomonocytic--immunology
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--analysis
Cell Differentiation--drug effects
Combined Modality Therapy
Cytarabine--administration & dosage
Daunorubicin--administration & dosage
Disease-Free Survival
Female
Humans
Idarubicin--administration & dosage
Immunologic Factors--therapeutic use
Leukemia, Promyelocytic, Acute--mortality
Life Tables
Male
Middle Aged
Neoplasm Proteins
Neoplasm, Residual
Neutropenia--etiology
Nuclear Proteins
Oncogene Proteins, Fusion--analysis
Polymerase Chain Reaction
Promyelocytic Leukemia Protein
Receptors, Retinoic Acid--analysis
Remission Induction
Salvage Therapy
Sialic Acid Binding Ig-like Lectin 3
Survival Analysis
Transcription Factors--analysis
Treatment Outcome
Tretinoin--pharmacology
Tumor Suppressor Proteins